Age, anti-müllerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide

Journal of Ovarian Research

Volumn 8, Issue 1, 2015, Pages

  D'Avila, Ângela Marcon ^a   Biolchi, Vanderlei ^a   Capp, Edison ^a,b,c   Corleta, Helena Von Eye ^a,b,d  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d GENERAR   (Brazil)

Author keywords

Amenorrhea related chemotherapy; Anovulation related chemotherapy; Anti M llerian hormone; Antral follicles count; Ovarian reserve

Indexed keywords

CYCLOPHOSPHAMIDE; MUELLERIAN INHIBITING FACTOR; ALKYLATING AGENT;

ADULT; AGE; AMENORRHEA; ANTRAL FOLLICLE COUNT; AREA UNDER THE CURVE; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; FEMALE; FEMALE GENITAL TRACT PARAMETERS; HUMAN; OLIGOMENORRHEA; OVARIAN RESERVE; OVARY FOLLICLE; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM;

ADULT; AGE FACTORS; AGED; AMENORRHEA; ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; OLIGOMENORRHEA; OVARIAN FOLLICLE; RISK ASSESSMENT;

EID: 84949985400     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/s13048-015-0209-4     Document Type: Article

References (24)

1. Rosen MP, Johnstone E, McCulloch CE, Schuh-Huerta SM, Sternfeld B, Reijo-Pera RA, et al. A characterization of the relationship of ovarian reserve markers with age. Fertil Steril. 2012;97(1):238-43.
2. Knopman JM, Papadopoulos EB, Grifo JA, Fino ME, Noyes N. Surviving childhood and reproductive-age malignancy: effects on fertility and future parenthood. Lancet Oncol. 2010;11(5):490-8.
3. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61(6):409-18.
4. Gracia CR, Sammel MD, Freeman E, Prewitt M, Carlson C, Ray A, et al. Impact of cancer therapies on ovarian reserve. Fertil Steril. 2012;97(1):134-40. e131.
5. Stroud JS, Mutch D, Rader J, Powell M, Thaker PH, Grigsby PW. Effects of cancer treatment on ovarian function. Fertil Steril. 2009;92(2):417-27.
6. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist. 2006;11(5):422-34.
7. Anderson RA, Wallace WH. Antimullerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertil Steril. 2013;99(6):1469-75.
8. Practice Committee of the American Society for Reproductive M. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2012;98(6):1407-15.
9. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12(6):685-718.
10. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertility and sterility. 2012; 98(6): 1407-1415
11. Bozza C, Puglisi F, Lambertini M, Osa EO, Manno M, Del Mastro L. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients. Endocr Relat Cancer. 2014;21(1):R51-65.
12. van Rooij IA, Tonkelaar I, Broekmans FJ, Looman CW, Scheffer GJ, de Jong FH, et al. Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause. 2004;11(6 Pt 1):601-6.
13. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001;344(26):1997-2008.
14. Dillon KE, Sammel MD, Prewitt M, Ginsberg JP, Walker D, Mersereau JE, et al. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013;99(2):477-83.
15. Dunlop CE, Anderson RA. Uses of anti-Mullerian hormone (AMH) measurement before and after cancer treatment in women. Maturitas. 2015;80(3):245-50.
16. Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011;96(5):1336-43.
17. Lutchman Singh K, Muttukrishna S, Stein RC, McGarrigle HH, Patel A, Parikh B, et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer. 2007;96(12):1808-16.
18. Strowitzki T, Capp E, von Eye CH. The degree of cycle irregularity correlates with the grade of endocrine and metabolic disorders in PCOS patients. Eur J Obstet Gynecol Reprod Biol. 2010;149(2):178-81.
19. Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24(7):1045-51.
20. Tiong V, Rozita AM, Taib NA, Yip CH, Ng CH. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer. World J Surg. 2014;38(9):2288-96.
21. Jung M, Shin HJ, Rha SY, Jeung HC, Hong S, Moon YW, et al. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. Ann Surg Oncol. 2010;17(12):3259-68.
22. Anders C, Marcom PK, Peterson B, Gu L, Unruhe S, Welch R, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest. 2008;26(3):286-95.
23. Long WQ, Ranchin V, Pautier P, Belville C, Denizot P, Cailla H, et al. Detection of minimal levels of serum anti-Mullerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab. 2000;85(2):540-4.
24. Broekmans FJ, de Ziegler D, Howles CM, Gougeon A, Trew G, Olivennes F. The antral follicle count: practical recommendations for better standardization. Fertil Steril. 2010;94(3):1044-51.